论文部分内容阅读
目的评价脑栓通胶囊治疗急性脑梗死的临床疗效及其可能的机制。方法 3组基础治疗相同,中药干预组加予口服脑栓通胶囊,中药安慰剂组加予口服中药安慰剂(淀粉),空白对照组只予基础治疗,治疗时间1个月。3组对象在治疗前、后接受以下评定:神经功能缺损程度评定量表(CSS),肢体运动功能评定量表(FIM),日常生活活动能力评定量表(MBI),对结果进行比较。结果 3组治疗后CSS评分、FIM评分和MBI评分经自身对照均具有统计学差异,而中药干预组评分的差异更明显,分别与中药安慰剂组及空白对照组治疗后比较差异均有显著性意义(P<0.005);中药安慰剂组与空白对照组治疗后比较差异无显著性意义(P>0.005)。结论脑栓通胶囊可促进急性脑梗死患者神经缺损功能的恢复,改善患者的肢体运动功能,提高患者的日常生活活动能力。
Objective To evaluate the clinical efficacy and the possible mechanism of Naoshuantong Capsule in the treatment of acute cerebral infarction. The third group received the same basic treatment. The traditional Chinese medicine intervention group was given oral Naoshuantong Capsule. The traditional Chinese medicine placebo group was given oral Chinese medicine placebo (starch). The blank control group was given only basic treatment for one month. The three groups received the following assessments before and after treatment: CSS, FIM, and MBI, and compared the results. Results The CSS scores, FIM scores and MBI scores of three groups after treatment were statistically different from those of the self-control group, but the scores of TCM intervention group were more obvious, which were significantly different from those of the placebo group and the blank control group (P <0.005). There was no significant difference between the placebo group and the blank control group after treatment (P> 0.005). Conclusion Naoshitong Capsule can promote the recovery of nerve defect function in patients with acute cerebral infarction, improve limb motor function and improve patients’ activities of daily living.